… G Horneff1, … Schmeling H , Mathony K, John V, Keyßer G, Burdach St Horneff G. Combination
of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis – a …

Uveitis in juvenile idiopathic arthritis (JIA) is frequently associated with the development of
complications and visual loss. Topical corticosteroids are the first-choice therapy, and …

Objective To develop criteria for the classification of macrophage activation syndrome (MAS)
in patients with systemic juvenile idiopathic arthritis (JIA). Methods A multistep process, …

Background Uveitis in juvenile idiopathic arthritis (JIAU) is frequently associated with the
development of complications and visual loss. Topical corticosteroids are the first line therapy, …

Background Interleukin-1 is pivotal in the pathogenesis of systemic juvenile idiopathic arthritis
(JIA). We assessed the efficacy and safety of canakinumab, a selective, fully human, anti–…

Background Tumor necrosis factor (TNF) has a pathogenic role in juvenile rheumatoid
arthritis. We evaluated the efficacy and safety of adalimumab, a fully human monoclonal anti-TNF …

Objective Juvenile localized scleroderma is usually considered a disease that is confined to
the skin and subcutaneous tissue. We studied the prevalence and clinical features of …

Objective: Etanercept monotherapy has been studied and approved for treatment of polyarticular
juvenile idiopathic arthritis (JIA). The following study evaluates the safety and efficacy of …

Mutations of the Activation-Induced Cytidine Deaminase (AID) gene have been found in
patients with autosomal recessive hyper-IgM (HIGM) syndrome type 2. We retrospectively …

Background We compared the safety and efficacy of leflunomide with that of methotrexate in
the treatment of polyarticular juvenile rheumatoid arthritis in a multinational, randomized, …